Enliven Total Current Liabilities from 2010 to 2025
| ELVN Stock | 21.07 0.44 2.05% |
Total Current Liabilities | First Reported 2019-12-31 | Previous Quarter 17 M | Current Value 15.9 M | Quarterly Volatility 7.1 M |
Check Enliven Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enliven Therapeutics' main balance sheet or income statement drivers, such as Other Operating Expenses of 100.9 M, Research Development of 84.8 M or Total Operating Expenses of 109.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.59. Enliven financial statements analysis is a perfect complement when working with Enliven Therapeutics Valuation or Volatility modules.
Enliven | Total Current Liabilities |
Latest Enliven Therapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Enliven Therapeutics over the last few years. Total Current Liabilities is an item on Enliven Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Enliven Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Enliven Therapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enliven Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Enliven Total Current Liabilities Regression Statistics
| Arithmetic Mean | 5,025,907 | |
| Geometric Mean | 2,274,150 | |
| Coefficient Of Variation | 141.36 | |
| Mean Deviation | 5,146,122 | |
| Median | 1,478,000 | |
| Standard Deviation | 7,104,546 | |
| Sample Variance | 50.5T | |
| Range | 25.1M | |
| R-Value | 0.71 | |
| Mean Square Error | 26.6T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 1,064,279 | |
| Total Sum of Squares | 757.1T |
Enliven Total Current Liabilities History
About Enliven Therapeutics Financial Statements
Enliven Therapeutics investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Enliven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 15.9 M | 9 M |
Check out the analysis of Enliven Therapeutics Correlation against competitors. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.